Journal
INTERNAL MEDICINE
Volume 56, Issue 14, Pages 1825-1829Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.56.8040
Keywords
gastric hyperplastic polyp; Helicobacter pylori; proton pump inhibitor; gastrin receptor; gastrin
Categories
Funding
- Chugai Pharmaceutical Co., Ltd.
- Bristol-Myers Squibb
- Eisai Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- AstraZeneca K. K.
- Astellas Pharma Inc.
Ask authors/readers for more resources
A 56-year-old man with gastroesophageal reflux disease (GERD) was referred to our hospital. Esophagogastroduodenoscopy (EGD) revealed no evidence of any polypoid lesions in the stomach, and the patient had no history of Helicobacter pylori infection. He received omeprazole (20 mg) once daily for the GERD. EGD was performed at 1 year after the start of omeprazole administration, and this time, gastric hyperplastic polyps (GHPs) were detected. The GHPs increased in size as the omeprazole treatment continued, but they markedly decreased in size following omeprazole discontinuation. Thus, the administration of proton pump inhibitors may be a risk factor for the development of GHP independent of H. pylori infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available